<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Noradrenaline — Clinical Reference</title>
<meta name="description" content="Evidence-based clinical reference for noradrenaline in septic shock. Dosing, calculations, SOAP II, VASST, Surviving Sepsis Campaign 2021.">
<link rel="preconnect" href="https://fonts.googleapis.com">
<link href="https://fonts.googleapis.com/css2?family=IBM+Plex+Mono:wght@400;500&family=IBM+Plex+Sans:wght@300;400;500;600&family=IBM+Plex+Serif:ital,wght@0,400;1,400&display=swap" rel="stylesheet">
<style>

/* ──────────────────────────────────────────────
   RESET & TOKENS
────────────────────────────────────────────── */
*, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }

:root {
  --bg:        #f5f4f0;
  --surface:   #ffffff;
  --border:    #d8d6cf;
  --text:      #1a1917;
  --muted:     #6b6860;
  --accent:    #1a3a5c;   /* deep navy */
  --accent2:   #b5401a;   /* terracotta */
  --low:       #e8f4e8;
  --mid:       #fef8e7;
  --high:      #fdecea;
  --mono:      'IBM Plex Mono', monospace;
  --sans:      'IBM Plex Sans', system-ui, sans-serif;
  --serif:     'IBM Plex Serif', Georgia, serif;
  --radius:    6px;
  --shadow:    0 1px 4px rgba(0,0,0,.08), 0 4px 16px rgba(0,0,0,.06);
}

html { font-size: 15px; }

body {
  font-family: var(--sans);
  background: var(--bg);
  color: var(--text);
  line-height: 1.65;
  min-height: 100vh;
}

/* ──────────────────────────────────────────────
   LAYOUT SHELL
────────────────────────────────────────────── */
.shell {
  max-width: 960px;
  margin: 0 auto;
  padding: 0 24px 80px;
}

/* ──────────────────────────────────────────────
   MASTHEAD
────────────────────────────────────────────── */
.masthead {
  padding: 52px 0 36px;
  border-bottom: 2px solid var(--text);
  margin-bottom: 36px;
}

.masthead-label {
  font-family: var(--mono);
  font-size: .72rem;
  letter-spacing: .12em;
  text-transform: uppercase;
  color: var(--muted);
  margin-bottom: 10px;
}

.masthead h1 {
  font-family: var(--serif);
  font-size: clamp(2.4rem, 5vw, 3.6rem);
  font-weight: 400;
  line-height: 1.1;
  letter-spacing: -.02em;
  color: var(--accent);
}

.masthead-sub {
  margin-top: 12px;
  font-size: .88rem;
  color: var(--muted);
  font-family: var(--mono);
}

/* ──────────────────────────────────────────────
   NAVIGATION
────────────────────────────────────────────── */
.nav {
  display: flex;
  flex-wrap: wrap;
  gap: 2px;
  margin-bottom: 44px;
  border-bottom: 1px solid var(--border);
  padding-bottom: 0;
}

.nav-btn {
  font-family: var(--mono);
  font-size: .78rem;
  letter-spacing: .04em;
  text-transform: uppercase;
  background: none;
  border: none;
  padding: 10px 18px;
  cursor: pointer;
  color: var(--muted);
  border-bottom: 2px solid transparent;
  margin-bottom: -1px;
  transition: color .15s, border-color .15s;
}

.nav-btn:hover { color: var(--text); }
.nav-btn.active { color: var(--accent); border-bottom-color: var(--accent); }

/* ──────────────────────────────────────────────
   TAB SYSTEM
────────────────────────────────────────────── */
.tab-content { display: none; }
.tab-content.active { display: block; animation: fadeIn .2s ease; }

@keyframes fadeIn { from { opacity: 0; transform: translateY(4px); } to { opacity: 1; transform: translateY(0); } }

/* ──────────────────────────────────────────────
   SECTION HEADING
────────────────────────────────────────────── */
.section-heading {
  font-family: var(--mono);
  font-size: .72rem;
  letter-spacing: .14em;
  text-transform: uppercase;
  color: var(--muted);
  margin-bottom: 6px;
}

h2.block-title {
  font-family: var(--serif);
  font-size: 1.6rem;
  font-weight: 400;
  color: var(--accent);
  margin-bottom: 28px;
  padding-bottom: 14px;
  border-bottom: 1px solid var(--border);
}

/* ──────────────────────────────────────────────
   CARDS
────────────────────────────────────────────── */
.card {
  background: var(--surface);
  border: 1px solid var(--border);
  border-radius: var(--radius);
  padding: 28px;
  margin-bottom: 20px;
}

.card-title {
  font-family: var(--sans);
  font-size: .95rem;
  font-weight: 600;
  color: var(--accent);
  margin-bottom: 14px;
  display: flex;
  align-items: center;
  gap: 8px;
}

.card-title .icon {
  font-size: 1rem;
}

.card p { color: var(--muted); font-size: .9rem; margin-bottom: 10px; }
.card p:last-child { margin-bottom: 0; }
.card ul { margin-left: 18px; color: var(--muted); font-size: .9rem; }
.card li { margin-bottom: 5px; }
.card strong { color: var(--text); font-weight: 500; }

.grid-2 { display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin-bottom: 24px; }
.grid-3 { display: grid; grid-template-columns: repeat(3, 1fr); gap: 20px; margin-bottom: 24px; }

/* ──────────────────────────────────────────────
   ALERT BOXES
────────────────────────────────────────────── */
.alert {
  border-left: 3px solid var(--accent);
  padding: 16px 20px;
  margin-bottom: 24px;
  font-size: .88rem;
  border-radius: 0 var(--radius) var(--radius) 0;
}

.alert-navy { background: #edf2f7; border-color: var(--accent); }
.alert-red   { background: #fdf2f0; border-color: var(--accent2); }
.alert-green { background: #f0f7f0; border-color: #2a7a2a; }
.alert-amber { background: #fefbf0; border-color: #c47c00; }

.alert strong { display: block; font-size: .8rem; font-family: var(--mono); letter-spacing: .06em; text-transform: uppercase; margin-bottom: 6px; color: var(--text); }

/* ──────────────────────────────────────────────
   DOSAGE TABLES
────────────────────────────────────────────── */
.strength-grid {
  display: grid;
  grid-template-columns: repeat(3, 1fr);
  gap: 20px;
  margin-bottom: 32px;
}

.strength-card {
  background: var(--surface);
  border: 1px solid var(--border);
  border-radius: var(--radius);
  overflow: hidden;
}

.strength-header {
  padding: 14px 20px;
  font-family: var(--mono);
  font-size: .75rem;
  letter-spacing: .08em;
  text-transform: uppercase;
  color: white;
  font-weight: 500;
}

.s-single .strength-header  { background: var(--accent); }
.s-double .strength-header  { background: #2a5a8c; }
.s-quad   .strength-header  { background: var(--accent2); }

.strength-body { padding: 16px 20px; }

.prep-info {
  font-size: .82rem;
  color: var(--muted);
  margin-bottom: 10px;
  padding-bottom: 10px;
  border-bottom: 1px solid var(--border);
}

.prep-info strong { color: var(--text); font-weight: 500; }

.formula {
  font-family: var(--mono);
  font-size: .8rem;
  background: #f0f0ea;
  padding: 8px 12px;
  border-radius: 3px;
  margin-bottom: 14px;
  color: var(--accent);
}

.dosage-table {
  width: 100%;
  border-collapse: collapse;
  font-size: .8rem;
}

.dosage-table th {
  background: #f5f4f0;
  padding: 8px 6px;
  text-align: center;
  font-weight: 500;
  font-family: var(--mono);
  font-size: .7rem;
  letter-spacing: .04em;
  text-transform: uppercase;
  color: var(--muted);
  border-bottom: 1px solid var(--border);
}

.dosage-table td {
  padding: 7px 6px;
  text-align: center;
  border-bottom: 1px solid #ece9e0;
  font-family: var(--mono);
  font-size: .79rem;
}

.dosage-table td:last-child {
  font-family: var(--sans);
  font-size: .75rem;
  color: var(--muted);
  text-align: left;
}

.dosage-table tr.low-dose  td { background: var(--low); }
.dosage-table tr.mid-dose  td { background: var(--mid); }
.dosage-table tr.high-dose td { background: var(--high); }

.dose-legend {
  display: flex;
  gap: 12px;
  font-size: .75rem;
  color: var(--muted);
  font-family: var(--mono);
  margin-bottom: 20px;
  flex-wrap: wrap;
}

.legend-dot {
  width: 10px; height: 10px;
  border-radius: 2px;
  display: inline-block;
  margin-right: 4px;
  vertical-align: middle;
}

/* ──────────────────────────────────────────────
   CALCULATION STEPS
────────────────────────────────────────────── */
.step-block {
  background: var(--surface);
  border: 1px solid var(--border);
  border-radius: var(--radius);
  margin-bottom: 20px;
  overflow: hidden;
}

.step-label {
  display: flex;
  align-items: center;
  gap: 14px;
  padding: 18px 24px;
  background: var(--accent);
  color: white;
}

.step-num {
  font-family: var(--mono);
  font-size: .72rem;
  letter-spacing: .1em;
  text-transform: uppercase;
  opacity: .7;
}

.step-name {
  font-weight: 500;
  font-size: .95rem;
}

.step-body { padding: 22px 24px; }

.calc-box {
  font-family: var(--mono);
  font-size: .84rem;
  background: #f0f0ea;
  border: 1px solid var(--border);
  border-radius: var(--radius);
  padding: 14px 18px;
  margin: 14px 0;
  line-height: 1.8;
  color: var(--text);
}

.calc-box strong {
  color: var(--accent);
}

/* ──────────────────────────────────────────────
   CONVERSION TABLE
────────────────────────────────────────────── */
.conv-table {
  width: 100%;
  border-collapse: collapse;
  margin-top: 16px;
  font-size: .85rem;
}

.conv-table th {
  font-family: var(--mono);
  font-size: .72rem;
  text-transform: uppercase;
  letter-spacing: .06em;
  padding: 10px 14px;
  background: var(--accent);
  color: white;
  text-align: left;
}

.conv-table td {
  padding: 10px 14px;
  border-bottom: 1px solid var(--border);
  font-family: var(--mono);
  font-size: .82rem;
}

.conv-table tr:last-child td { border-bottom: none; }
.conv-table tr:nth-child(even) td { background: #f8f8f4; }

/* ──────────────────────────────────────────────
   EVIDENCE TRIALS
────────────────────────────────────────────── */
.trial-card {
  background: var(--surface);
  border: 1px solid var(--border);
  border-radius: var(--radius);
  padding: 26px 28px;
  margin-bottom: 20px;
  border-left: 4px solid var(--accent);
}

.trial-header {
  display: flex;
  align-items: flex-start;
  justify-content: space-between;
  gap: 16px;
  margin-bottom: 12px;
  flex-wrap: wrap;
}

.trial-title {
  font-size: 1rem;
  font-weight: 600;
  color: var(--text);
  line-height: 1.3;
}

.trial-badge {
  font-family: var(--mono);
  font-size: .72rem;
  letter-spacing: .06em;
  background: var(--accent);
  color: white;
  padding: 4px 10px;
  border-radius: 20px;
  white-space: nowrap;
  flex-shrink: 0;
}

.trial-meta {
  font-size: .82rem;
  color: var(--muted);
  margin-bottom: 14px;
  font-style: italic;
}

.trial-findings {
  font-size: .88rem;
  color: var(--text);
}

.trial-findings p {
  margin-bottom: 8px;
  color: var(--muted);
}

.finding-row {
  display: flex;
  align-items: baseline;
  gap: 8px;
  margin: 5px 0;
  font-size: .86rem;
}

.finding-row::before {
  content: '—';
  color: var(--muted);
  flex-shrink: 0;
  font-family: var(--mono);
}

.stat-highlight {
  font-family: var(--mono);
  font-size: .82rem;
  background: #edf2f7;
  color: var(--accent);
  padding: 2px 7px;
  border-radius: 3px;
  white-space: nowrap;
}

.stat-danger {
  background: #fdf2f0;
  color: var(--accent2);
}

.correction-note {
  background: #fefbf0;
  border: 1px solid #e8d070;
  border-radius: var(--radius);
  padding: 12px 16px;
  font-size: .82rem;
  color: #7a6000;
  margin-top: 12px;
}

.correction-note strong { color: #5a4500; }

/* ──────────────────────────────────────────────
   TIMELINE
────────────────────────────────────────────── */
.timeline {
  position: relative;
  padding-left: 36px;
}

.timeline::before {
  content: '';
  position: absolute;
  left: 8px;
  top: 6px;
  bottom: 6px;
  width: 1px;
  background: var(--border);
}

.tl-item {
  position: relative;
  margin-bottom: 28px;
}

.tl-item::before {
  content: '';
  position: absolute;
  left: -31px;
  top: 7px;
  width: 8px;
  height: 8px;
  border-radius: 50%;
  background: var(--accent);
  border: 2px solid var(--bg);
  outline: 1px solid var(--accent);
}

.tl-year {
  font-family: var(--mono);
  font-size: .75rem;
  color: var(--accent);
  letter-spacing: .06em;
  margin-bottom: 4px;
}

.tl-event {
  font-weight: 500;
  font-size: .92rem;
  margin-bottom: 4px;
}

.tl-desc {
  font-size: .84rem;
  color: var(--muted);
  line-height: 1.5;
}

/* ──────────────────────────────────────────────
   REFERENCES
────────────────────────────────────────────── */
.ref-list {
  list-style: none;
  counter-reset: ref;
}

.ref-list li {
  counter-increment: ref;
  display: flex;
  gap: 14px;
  margin-bottom: 16px;
  font-size: .83rem;
  color: var(--muted);
  line-height: 1.55;
}

.ref-list li::before {
  content: counter(ref);
  font-family: var(--mono);
  font-size: .72rem;
  min-width: 22px;
  height: 22px;
  background: var(--accent);
  color: white;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  flex-shrink: 0;
  margin-top: 1px;
}

.ref-list em { font-style: italic; }

/* ──────────────────────────────────────────────
   CLINICAL NOTES BLOCK
────────────────────────────────────────────── */
.notes-block {
  background: var(--accent);
  color: white;
  border-radius: var(--radius);
  padding: 26px 28px;
  margin: 28px 0;
}

.notes-block h3 {
  font-family: var(--mono);
  font-size: .72rem;
  letter-spacing: .12em;
  text-transform: uppercase;
  opacity: .7;
  margin-bottom: 14px;
}

.notes-block ul {
  list-style: none;
  display: grid;
  grid-template-columns: 1fr 1fr;
  gap: 8px 24px;
}

.notes-block li {
  font-size: .85rem;
  padding-left: 16px;
  position: relative;
  line-height: 1.5;
}

.notes-block li::before {
  content: '›';
  position: absolute;
  left: 0;
  opacity: .6;
  font-size: 1rem;
  top: -1px;
}

.notes-block strong { opacity: .9; }

/* ──────────────────────────────────────────────
   FOOTER
────────────────────────────────────────────── */
footer {
  margin-top: 60px;
  padding-top: 24px;
  border-top: 1px solid var(--border);
  display: flex;
  justify-content: space-between;
  align-items: flex-start;
  gap: 20px;
  flex-wrap: wrap;
}

.footer-left {
  font-family: var(--mono);
  font-size: .72rem;
  color: var(--muted);
  line-height: 1.7;
}

.footer-badge {
  font-family: var(--mono);
  font-size: .7rem;
  padding: 5px 10px;
  border: 1px solid var(--border);
  border-radius: 20px;
  color: var(--muted);
  white-space: nowrap;
  align-self: center;
}

/* ──────────────────────────────────────────────
   RESPONSIVE
────────────────────────────────────────────── */
@media (max-width: 720px) {
  .grid-2, .grid-3 { grid-template-columns: 1fr; }
  .strength-grid   { grid-template-columns: 1fr; }
  .notes-block ul  { grid-template-columns: 1fr; }
  .shell { padding: 0 16px 60px; }
  footer { flex-direction: column; }
}

</style>
</head>
<body>

<div class="shell">

  <!-- MASTHEAD -->
  <header class="masthead">
    <p class="masthead-label">Critical Care Reference · Vasopressor</p>
    <h1>Noradrenaline<br><span style="font-size:.55em; color:var(--muted); font-style:italic;">(Norepinephrine)</span></h1>
    <p class="masthead-sub">Evidence-based clinical guide · Updated January 2025 · SSC 2021 aligned</p>
  </header>

  <!-- NAV -->
  <nav class="nav">
    <button class="nav-btn active" onclick="showTab('intro',this)">Overview</button>
    <button class="nav-btn" onclick="showTab('dosage',this)">Dosage Tables</button>
    <button class="nav-btn" onclick="showTab('calcs',this)">Calculations</button>
    <button class="nav-btn" onclick="showTab('evidence',this)">Evidence</button>
    <button class="nav-btn" onclick="showTab('timeline',this)">Timeline</button>
    <button class="nav-btn" onclick="showTab('refs',this)">References</button>
  </nav>

  <!-- ═══════════════════════════════ TAB: OVERVIEW ═══════════════════════════════ -->
  <section id="intro" class="tab-content active">
    <p class="section-heading">Overview</p>
    <h2 class="block-title">Introduction to Noradrenaline</h2>

    <div class="grid-2">
      <div class="card">
        <div class="card-title"><span class="icon">⬡</span>Pharmacology</div>
        <p><strong>Noradrenaline (norepinephrine)</strong> is an endogenous catecholamine acting as both a neurotransmitter and circulating hormone. It is the primary sympathetic neurotransmitter.</p>
        <ul>
          <li><strong>Primary action:</strong> α<sub>1</sub>-adrenoceptor agonist → vasoconstriction</li>
          <li><strong>Secondary action:</strong> β<sub>1</sub>-adrenoceptor agonism → modest positive inotropy</li>
          <li><strong>Net haemodynamic effect:</strong> ↑ SVR, ↑ MAP, minimal heart rate change</li>
          <li><strong>Plasma half-life:</strong> approximately 2–3 minutes</li>
          <li><strong>Metabolism:</strong> MAO (neuronal reuptake) and COMT (extraneuronal)</li>
          <li><strong>Elimination:</strong> primarily hepatic and renal</li>
        </ul>
      </div>

      <div class="card">
        <div class="card-title"><span class="icon">⬡</span>Clinical Indications</div>
        <p>Noradrenaline is the <strong>first-line vasopressor</strong> for septic shock per the Surviving Sepsis Campaign (SSC 2021) guidelines, recommended as a strong, evidence-based intervention.</p>
        <ul>
          <li>Septic shock (first-line, strong recommendation)</li>
          <li>Vasodilatory / distributive shock (other causes)</li>
          <li>Adjunct in cardiogenic shock with systemic vasodilation</li>
          <li>Post-operative hypotension refractory to fluid challenge</li>
        </ul>
      </div>
    </div>

    <div class="alert alert-navy">
      <strong>Key Clinical Points</strong>
      Standard ampule: 4 mg / 2 ml (2 mg/ml) · First-line over dopamine (SSC 2021) · Target MAP ≥ 65 mmHg · Central venous access required for concentrations > 80 mcg/ml · Avoid peripheral administration of concentrated solutions
    </div>

    <div class="grid-2">
      <div class="card">
        <div class="card-title"><span class="icon">✓</span>Advantages over Dopamine</div>
        <ul>
          <li><strong>Lower arrhythmia risk</strong> (12.4% vs 24.1%, SOAP II)</li>
          <li>More predictable, linear dose-response</li>
          <li>Does not stimulate dopaminergic receptors at clinical doses</li>
          <li>No evidence of "low-dose renal protection" with dopamine (SSC guideline)</li>
          <li>Extensive evidence base across multiple RCTs and meta-analyses</li>
        </ul>
      </div>

      <div class="card">
        <div class="card-title"><span class="icon">△</span>Adverse Effects & Cautions</div>
        <ul>
          <li><strong>Tissue necrosis</strong> if extravasation occurs (use central line)</li>
          <li>↓ Splanchnic and mesenteric blood flow at high doses</li>
          <li>Digital / limb ischaemia with prolonged high-dose infusion</li>
          <li>Contraindicated in uncorrected hypovolaemia</li>
          <li>Can worsen hypertension — monitor continuously</li>
          <li>Caution in severe peripheral vascular disease</li>
        </ul>
      </div>
    </div>

    <div class="card">
      <div class="card-title"><span class="icon">⬡</span>Surviving Sepsis Campaign 2021 — Vasopressor Recommendations</div>
      <ul>
        <li><strong>Noradrenaline</strong> as first-line vasopressor for septic shock (strong recommendation)</li>
        <li>Add <strong>vasopressin</strong> (0.03 U/min fixed dose) to noradrenaline rather than escalating dose, when MAP target not met (weak recommendation, moderate evidence)</li>
        <li>Add <strong>adrenaline</strong> to noradrenaline as a second-line agent when target MAP not achieved (weak recommendation, low quality evidence)</li>
        <li>Do <strong>not</strong> use low-dose dopamine for renal protection (strong recommendation, high quality evidence)</li>
        <li>Target MAP <strong>≥ 65 mmHg</strong> during initial resuscitation (strong recommendation)</li>
        <li>Suggest individualising MAP targets in patients with chronic hypertension or known atherosclerotic disease (weak recommendation)</li>
        <li><strong>Early initiation</strong> of vasopressors — do not delay to complete fluid loading</li>
      </ul>
    </div>
  </section>

  <!-- ═══════════════════════════════ TAB: DOSAGE TABLES ═══════════════════════════════ -->
  <section id="dosage" class="tab-content">
    <p class="section-heading">Reference Tables</p>
    <h2 class="block-title">Noradrenaline Dosage Tables — Syringe Pump</h2>

    <div class="alert alert-amber">
      <strong>Preparation Standard</strong>
      Ampule: 4 mg / 2 ml (2 mg/ml) · Diluent: 5% Dextrose (D5W) or 0.9% NaCl · Total syringe volume: 50 ml · All infusions below require a dedicated central venous lumen. A note on formulations: in many countries noradrenaline is supplied as the <em>tartrate salt</em>; confirm your local ampule concentration before preparation.
    </div>

    <div class="dose-legend">
      <span><span class="legend-dot" style="background:#c5e5c5;"></span>Low dose</span>
      <span><span class="legend-dot" style="background:#fce9a0;"></span>Moderate dose</span>
      <span><span class="legend-dot" style="background:#f5b8b0;"></span>High dose — consider adjunct vasopressor</span>
    </div>

    <div class="strength-grid">

      <!-- SINGLE -->
      <div class="strength-card s-single">
        <div class="strength-header">Single Strength — 1 Ampule</div>
        <div class="strength-body">
          <div class="prep-info">
            <strong>4 mg + D5W → 50 ml</strong><br>
            Concentration: <strong>80 mcg/ml</strong>
          </div>
          <div class="formula">mcg/min = ml/hr × 1.33</div>
          <table class="dosage-table">
            <thead>
              <tr>
                <th>ml/hr</th>
                <th>mcg/min</th>
                <th>mcg/kg/min<br>(70 kg)</th>
                <th>Context</th>
              </tr>
            </thead>
            <tbody>
              <tr class="low-dose"><td>1</td><td>1.3</td><td>0.019</td><td>Initiation</td></tr>
              <tr class="low-dose"><td>2</td><td>2.7</td><td>0.038</td><td>Low support</td></tr>
              <tr class="low-dose"><td>3</td><td>4.0</td><td>0.057</td><td>Low–moderate</td></tr>
              <tr class="low-dose"><td>4</td><td>5.3</td><td>0.076</td><td>Moderate</td></tr>
              <tr class="mid-dose"><td>5</td><td>6.7</td><td>0.095</td><td>Moderate</td></tr>
              <tr class="mid-dose"><td>7</td><td>9.3</td><td>0.133</td><td>Higher</td></tr>
              <tr class="mid-dose"><td>10</td><td>13.3</td><td>0.190</td><td>Significant</td></tr>
              <tr class="high-dose"><td>15</td><td>20.0</td><td>0.286</td><td>High — escalate</td></tr>
            </tbody>
          </table>
        </div>
      </div>

      <!-- DOUBLE -->
      <div class="strength-card s-double">
        <div class="strength-header">Double Strength — 2 Ampules</div>
        <div class="strength-body">
          <div class="prep-info">
            <strong>8 mg + D5W → 50 ml</strong><br>
            Concentration: <strong>160 mcg/ml</strong>
          </div>
          <div class="formula">mcg/min = ml/hr × 2.67</div>
          <table class="dosage-table">
            <thead>
              <tr>
                <th>ml/hr</th>
                <th>mcg/min</th>
                <th>mcg/kg/min<br>(70 kg)</th>
                <th>Context</th>
              </tr>
            </thead>
            <tbody>
              <tr class="low-dose"><td>1</td><td>2.7</td><td>0.038</td><td>Low support</td></tr>
              <tr class="low-dose"><td>2</td><td>5.3</td><td>0.076</td><td>Moderate</td></tr>
              <tr class="mid-dose"><td>3</td><td>8.0</td><td>0.114</td><td>Moderate</td></tr>
              <tr class="mid-dose"><td>4</td><td>10.7</td><td>0.152</td><td>Higher</td></tr>
              <tr class="mid-dose"><td>5</td><td>13.3</td><td>0.190</td><td>Significant</td></tr>
              <tr class="mid-dose"><td>6</td><td>16.0</td><td>0.229</td><td>High</td></tr>
              <tr class="high-dose"><td>8</td><td>21.3</td><td>0.305</td><td>Escalate</td></tr>
              <tr class="high-dose"><td>10</td><td>26.7</td><td>0.381</td><td>Add vasopressin</td></tr>
            </tbody>
          </table>
        </div>
      </div>

      <!-- QUADRUPLE -->
      <div class="strength-card s-quad">
        <div class="strength-header">Quadruple Strength — 4 Ampules</div>
        <div class="strength-body">
          <div class="prep-info">
            <strong>16 mg + D5W → 50 ml</strong><br>
            Concentration: <strong>320 mcg/ml</strong>
          </div>
          <div class="formula">mcg/min = ml/hr × 5.33</div>
          <table class="dosage-table">
            <thead>
              <tr>
                <th>ml/hr</th>
                <th>mcg/min</th>
                <th>mcg/kg/min<br>(70 kg)</th>
                <th>Context</th>
              </tr>
            </thead>
            <tbody>
              <tr class="low-dose"><td>1</td><td>5.3</td><td>0.076</td><td>Moderate</td></tr>
              <tr class="mid-dose"><td>2</td><td>10.7</td><td>0.152</td><td>Higher</td></tr>
              <tr class="mid-dose"><td>3</td><td>16.0</td><td>0.229</td><td>High</td></tr>
              <tr class="high-dose"><td>4</td><td>21.3</td><td>0.305</td><td>Escalate</td></tr>
              <tr class="high-dose"><td>5</td><td>26.7</td><td>0.381</td><td>Add vasopressin</td></tr>
              <tr class="high-dose"><td>6</td><td>32.0</td><td>0.457</td><td>Max range</td></tr>
              <tr class="high-dose"><td>8</td><td>42.7</td><td>0.610</td><td>Refractory shock</td></tr>
              <tr class="high-dose"><td>10</td><td>53.3</td><td>0.762</td><td>Crisis — consider ECMO</td></tr>
            </tbody>
          </table>
        </div>
      </div>

    </div>

    <div class="notes-block">
      <h3>Clinical Notes</h3>
      <ul>
        <li><strong>Starting dose:</strong> 0.05–0.1 mcg/kg/min (SSC 2021)</li>
        <li><strong>Titrate:</strong> increment by 0.05–0.1 mcg/kg/min every 3–5 min</li>
        <li><strong>Add vasopressin</strong> at 0.03 U/min when dose ≥ 0.25–0.5 mcg/kg/min</li>
        <li><strong>Maximum:</strong> generally &lt; 1 mcg/kg/min before escalation</li>
        <li><strong>Central line:</strong> mandatory for concentrations &gt; 80 mcg/ml</li>
        <li><strong>Monitoring:</strong> continuous arterial BP, urine output, peripheral perfusion</li>
        <li><strong>Weaning:</strong> reduce by 25–50% increments every 30–60 min</li>
        <li><strong>Compatibility:</strong> D5W or 0.9% NaCl; avoid bicarbonate/alkaline solutions</li>
        <li><strong>Stability:</strong> use within 24 h of preparation; protect from light</li>
        <li><strong>Note:</strong> mcg/kg/min values for 70 kg reference patient only — recalculate for actual weight</li>
      </ul>
    </div>
  </section>

  <!-- ═══════════════════════════════ TAB: CALCULATIONS ═══════════════════════════════ -->
  <section id="calcs" class="tab-content">
    <p class="section-heading">Calculations</p>
    <h2 class="block-title">Dose Calculation — Step by Step</h2>

    <!-- STEP 1 -->
    <div class="step-block">
      <div class="step-label">
        <span class="step-num">Step 01</span>
        <span class="step-name">Understanding the Ampule</span>
      </div>
      <div class="step-body">
        <div class="alert alert-amber">
          <strong>Standard Ampule (most countries)</strong>
          4 mg noradrenaline base · 2 ml volume · Concentration = 2 mg/ml = 2,000 mcg/ml
        </div>
        <div class="calc-box">
          Ampule content (mcg) = 4 mg × 1000 = <strong>4,000 mcg per ampule</strong>
        </div>
        <div class="alert alert-red">
          <strong>Important — Formulation Clarification</strong>
          Some countries supply noradrenaline as the <em>tartrate salt</em> (e.g., 8 mg noradrenaline tartrate ≈ 4 mg noradrenaline base). Always verify your local ampule labelling. These tables use noradrenaline <em>base</em> equivalent.
        </div>
      </div>
    </div>

    <!-- STEP 2 -->
    <div class="step-block">
      <div class="step-label">
        <span class="step-num">Step 02</span>
        <span class="step-name">Calculating Final Concentration in a 50 ml Syringe</span>
      </div>
      <div class="step-body">
        <p style="font-size:.9rem; margin-bottom:14px; color:var(--muted);">Dilute the required number of ampules with D5W or 0.9% NaCl to reach a total syringe volume of 50 ml.</p>

        <div class="grid-3">
          <div class="calc-box">
            <strong>Single (1 ampule)</strong><br>
            4,000 mcg ÷ 50 ml<br>
            = <strong>80 mcg/ml</strong>
          </div>
          <div class="calc-box">
            <strong>Double (2 ampules)</strong><br>
            8,000 mcg ÷ 50 ml<br>
            = <strong>160 mcg/ml</strong>
          </div>
          <div class="calc-box">
            <strong>Quadruple (4 ampules)</strong><br>
            16,000 mcg ÷ 50 ml<br>
            = <strong>320 mcg/ml</strong>
          </div>
        </div>

        <div class="calc-box">
          <strong>General Formula:</strong><br>
          Concentration (mcg/ml) = (Number of ampules × 4,000 mcg) ÷ 50 ml
        </div>
      </div>
    </div>

    <!-- STEP 3 -->
    <div class="step-block">
      <div class="step-label">
        <span class="step-num">Step 03</span>
        <span class="step-name">Converting Pump Rate (ml/hr) to Dose (mcg/min)</span>
      </div>
      <div class="step-body">
        <div class="calc-box">
          <strong>Core Formula:</strong><br>
          mcg/min = (ml/hr × concentration in mcg/ml) ÷ 60
        </div>

        <p style="font-size:.88rem; color:var(--muted); margin: 14px 0 8px;">Why divide by 60? Because ml/hr × mcg/ml gives mcg per hour — divide by 60 to convert to mcg per minute.</p>

        <div class="alert alert-green">
          <strong>Worked Example — Double Strength, 70 kg Patient</strong>
          Preparation: 2 ampules (8 mg) in D5W to 50 ml → 160 mcg/ml<br><br>
          Pump set at: 5 ml/hr<br>
          mcg/hr = 5 ml/hr × 160 mcg/ml = 800 mcg/hr<br>
          mcg/min = 800 ÷ 60 = <strong>13.3 mcg/min</strong><br>
          mcg/kg/min = 13.3 ÷ 70 = <strong>0.19 mcg/kg/min</strong>
        </div>
      </div>
    </div>

    <!-- STEP 4 -->
    <div class="step-block">
      <div class="step-label">
        <span class="step-num">Step 04</span>
        <span class="step-name">Quick Conversion Factors</span>
      </div>
      <div class="step-body">
        <p style="font-size:.88rem; color:var(--muted); margin-bottom:14px;">To avoid manual calculation at the bedside, use these fixed multipliers:</p>

        <table class="conv-table">
          <thead>
            <tr>
              <th>Preparation</th>
              <th>Conc. (mcg/ml)</th>
              <th>Factor</th>
              <th>Quick formula</th>
              <th>Derivation</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>1 ampule (single)</td>
              <td>80</td>
              <td>1.33</td>
              <td>mcg/min = ml/hr × 1.33</td>
              <td>80 ÷ 60</td>
            </tr>
            <tr>
              <td>2 ampules (double)</td>
              <td>160</td>
              <td>2.67</td>
              <td>mcg/min = ml/hr × 2.67</td>
              <td>160 ÷ 60</td>
            </tr>
            <tr>
              <td>4 ampules (quadruple)</td>
              <td>320</td>
              <td>5.33</td>
              <td>mcg/min = ml/hr × 5.33</td>
              <td>320 ÷ 60</td>
            </tr>
          </tbody>
        </table>

        <div class="alert alert-amber" style="margin-top:16px;">
          <strong>Reverse Calculation — Target Dose to Pump Rate</strong>
          If you know the required dose in mcg/min, divide by the conversion factor to get ml/hr.<br>
          Example: Target 10 mcg/min on double strength → 10 ÷ 2.67 = <strong>3.75 ml/hr</strong>
        </div>
      </div>
    </div>

  </section>

  <!-- ═══════════════════════════════ TAB: EVIDENCE ═══════════════════════════════ -->
  <section id="evidence" class="tab-content">
    <p class="section-heading">Key Trials</p>
    <h2 class="block-title">Clinical Evidence Base</h2>

    <!-- SOAP II -->
    <div class="trial-card">
      <div class="trial-header">
        <div>
          <div class="trial-title">SOAP II — Comparison of Dopamine and Norepinephrine in the Treatment of Shock</div>
          <div class="trial-meta">De Backer D et al. SOAP II Investigators. N Engl J Med. 2010;362(9):779–789.</div>
        </div>
        <span class="trial-badge">2010 · N Engl J Med</span>
      </div>
      <div class="trial-findings">
        <p><strong>Design:</strong> Multicentre, randomised, double-blind trial. n = 1,679 (858 dopamine, 821 norepinephrine). All types of shock included (60% septic, 17% cardiogenic, 16% hypovolaemic).</p>

        <div class="finding-row">
          <strong>Primary outcome — 28-day mortality:</strong>&nbsp; <span class="stat-highlight">52.5% (dopamine) vs 48.5% (norepinephrine)</span>&nbsp; OR 1.17 (95% CI 0.97–1.42); <span class="stat-highlight">p = 0.10</span> — No significant difference
        </div>
        <div class="finding-row">
          <strong>Arrhythmic events:</strong>&nbsp; <span class="stat-danger">24.1% (dopamine) vs 12.4% (norepinephrine)</span>&nbsp; — p &lt; 0.001, highly significant reduction with norepinephrine
        </div>
        <div class="finding-row">
          <strong>Cardiogenic shock subgroup:</strong>&nbsp; Dopamine associated with significantly higher 28-day mortality in the 280 cardiogenic shock patients (p = 0.03). No significant difference in the 1,044 septic shock patients (p = 0.19).
        </div>
        <div class="finding-row">
          <strong>Conclusion:</strong> No difference in overall mortality, but dopamine carries significantly greater risk of arrhythmias and appears harmful in cardiogenic shock. This safety advantage established norepinephrine as the preferred agent.
        </div>

        <div class="correction-note">
          <strong>Framing clarification:</strong> SOAP II did <em>not</em> show norepinephrine was superior in mortality terms for the overall population. Its importance lies in demonstrating that dopamine is <em>less safe</em> — particularly its arrhythmia burden and cardiogenic shock signal — rather than norepinephrine having a direct mortality benefit. Subsequent Bayesian reanalysis (Vincent et al., 2024) found dopamine consistently disfavoured across all subgroups.
        </div>
      </div>
    </div>

    <!-- VASST -->
    <div class="trial-card">
      <div class="trial-header">
        <div>
          <div class="trial-title">VASST — Vasopressin versus Norepinephrine in Patients with Septic Shock</div>
          <div class="trial-meta">Russell JA et al. VASST Investigators. N Engl J Med. 2008;358(9):877–887.</div>
        </div>
        <span class="trial-badge">2008 · N Engl J Med</span>
      </div>
      <div class="trial-findings">
        <p><strong>Design:</strong> Multicentre, randomised, double-blind trial. n = 778 (396 vasopressin, 382 norepinephrine). Patients already receiving ≥ 5 mcg/min norepinephrine were randomised to <em>add</em> fixed-dose vasopressin (0.01–0.03 U/min) <em>vs add</em> additional norepinephrine — both groups were on catecholamines. This is effectively a vasopressin <em>adjunct</em> trial, not a direct head-to-head substitution.</p>

        <div class="finding-row">
          <strong>28-day mortality (vasopressin vs norepinephrine):</strong>&nbsp; <span class="stat-highlight">35.4% vs 39.3%; p = 0.26</span> — No significant difference
        </div>
        <div class="finding-row">
          <strong>90-day mortality:</strong>&nbsp; <span class="stat-highlight">43.9% vs 49.6%; p = 0.11</span> — No significant difference
        </div>
        <div class="finding-row">
          <strong>Less severe septic shock subgroup</strong> (norepinephrine &lt; 15 mcg/min at entry):&nbsp; <span class="stat-highlight">26.5% (vasopressin) vs 35.7% (norepinephrine); p = 0.05</span> — Trend favouring vasopressin (hypothesis-generating only; heterogeneity test not significant p = 0.10)
        </div>
        <div class="finding-row">
          <strong>Serious adverse events:</strong> 10.3% vs 10.5%; p = 1.00 — No difference
        </div>
        <div class="finding-row">
          <strong>Vasopressin sparing effect:</strong> Vasopressin group required significantly less norepinephrine (catecholamine-sparing effect confirmed)
        </div>

        <div class="correction-note">
          <strong>Design note:</strong> VASST tested the <em>addition</em> of vasopressin to background norepinephrine therapy, not vasopressin as a standalone replacement. The trial was underpowered (expected 60% mortality; observed 35–39%), making a type II error possible. The SSC 2021 guideline translates this into a recommendation to <em>add</em> vasopressin 0.03 U/min as a second agent to reduce norepinephrine dose.
        </div>
      </div>
    </div>

    <!-- VANISH -->
    <div class="trial-card">
      <div class="trial-header">
        <div>
          <div class="trial-title">VANISH — Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Septic Shock</div>
          <div class="trial-meta">Gordon AC et al. JAMA. 2016;316(5):509–518.</div>
        </div>
        <span class="trial-badge">2016 · JAMA</span>
      </div>
      <div class="trial-findings">
        <p><strong>Design:</strong> 2×2 factorial, randomised, double-blind. n = 409. Vasopressin (up to 0.06 U/min) vs norepinephrine as initial vasopressor. Primary outcome: kidney failure-free days.</p>
        <div class="finding-row">No significant difference in kidney failure-free days, 28-day mortality, or other organ outcomes between vasopressin and norepinephrine arms.
        </div>
        <div class="finding-row">
          <strong>RRT need:</strong>&nbsp; <span class="stat-highlight">25.4% (vasopressin) vs 35.3% (norepinephrine); p = 0.007</span> — significant reduction in RRT with vasopressin, but was not the pre-specified primary endpoint and should be interpreted with caution.
        </div>
      </div>
    </div>

    <!-- Early NE evidence -->
    <div class="trial-card">
      <div class="trial-header">
        <div>
          <div class="trial-title">Early Noradrenaline Initiation in Septic Shock — Meta-Analytic Evidence</div>
          <div class="trial-meta">Shi R et al. Crit Care. 2025;29(1):182 · Ahn C et al. Chest. 2024 · Li Y et al. J Intensive Med. 2025;5(2):160–166.</div>
        </div>
        <span class="trial-badge">2024–2025</span>
      </div>
      <div class="trial-findings">
        <p><strong>Summary of emerging evidence:</strong> Multiple meta-analyses and prospective cohort studies now suggest that earlier initiation of noradrenaline (within 1 hour of septic shock diagnosis) is associated with:</p>
        <div class="finding-row">Lower 28-day mortality compared with delayed initiation</div>
        <div class="finding-row">Faster achievement of MAP ≥ 65 mmHg</div>
        <div class="finding-row">Reduced 24-hour fluid resuscitation volumes (potential fluid-sparing effect)</div>
        <div class="finding-row">Higher early lactate clearance rates</div>

        <div class="correction-note">
          <strong>Evidence quality note:</strong> This emerging body of evidence is predominantly from observational studies and meta-analyses of heterogeneous trials. Randomised evidence on the optimal timing of vasopressor initiation (including VASOSHOCK) is ongoing. Current SSC 2021 guidelines support early vasopressor use but acknowledge the timing evidence as moderate quality.
        </div>
      </div>
    </div>

    <!-- SSC Guidelines -->
    <div class="trial-card" style="border-left-color: var(--accent2);">
      <div class="trial-header">
        <div>
          <div class="trial-title">Surviving Sepsis Campaign — Guideline Evolution (2004–2021)</div>
          <div class="trial-meta">Rhodes A et al. Intensive Care Med. 2017 (2016 guidelines) · Evans L et al. Intensive Care Med. 2021;47:1181–1247.</div>
        </div>
        <span class="trial-badge" style="background:var(--accent2);">Guidelines</span>
      </div>
      <div class="trial-findings">
        <div class="finding-row"><strong>2004:</strong> First SSC guidelines — dopamine and noradrenaline listed as equivalent first-line vasopressors</div>
        <div class="finding-row"><strong>2008:</strong> Both dopamine and noradrenaline recommended; growing concern about dopamine safety</div>
        <div class="finding-row"><strong>2012:</strong> Post-SOAP II — noradrenaline preferred over dopamine for most patients</div>
        <div class="finding-row"><strong>2016:</strong> Noradrenaline formally established as first-line vasopressor (strong recommendation)</div>
        <div class="finding-row"><strong>2021:</strong> Noradrenaline maintained as first-line; emphasis on early initiation, vasopressin as second-line adjunct (0.03 U/min fixed dose), and individualised MAP targets</div>
      </div>
    </div>

  </section>

  <!-- ═══════════════════════════════ TAB: TIMELINE ═══════════════════════════════ -->
  <section id="timeline" class="tab-content">
    <p class="section-heading">History</p>
    <h2 class="block-title">Evolution of Noradrenaline in Critical Care</h2>

    <div class="timeline">
      <div class="tl-item">
        <div class="tl-year">1901</div>
        <div class="tl-event">Adrenaline isolated by Jokichi Takamine</div>
        <div class="tl-desc">The discovery of adrenaline opened the era of catecholamine pharmacology and vasopressor therapy.</div>
      </div>
      <div class="tl-item">
        <div class="tl-year">1946</div>
        <div class="tl-event">Ulf von Euler identifies noradrenaline as the sympathetic neurotransmitter</div>
        <div class="tl-desc">Von Euler demonstrated that noradrenaline, not adrenaline, is the primary transmitter released at postganglionic sympathetic nerve terminals. This work later contributed to his 1970 Nobel Prize in Physiology or Medicine.</div>
      </div>
      <div class="tl-item">
        <div class="tl-year">1970s</div>
        <div class="tl-event">Early clinical use of noradrenaline in vasodilatory shock</div>
        <div class="tl-desc">Initial clinical applications emerged, though concerns about renal and splanchnic vasoconstriction limited its adoption. Dopamine — with its perceived "renal-protective" low-dose properties — remained widely preferred despite limited evidence for this effect.</div>
      </div>
      <div class="tl-item">
        <div class="tl-year">1991</div>
        <div class="tl-event">First ACCP/SCCM consensus definitions for sepsis and septic shock</div>
        <div class="tl-desc">Publication of the American College of Chest Physicians / Society of Critical Care Medicine consensus. Dopamine was the dominant vasopressor of the era.</div>
      </div>
      <div class="tl-item">
        <div class="tl-year">2001</div>
        <div class="tl-event">EGDT trial — Rivers et al.</div>
        <div class="tl-desc">The landmark early goal-directed therapy trial (N Engl J Med) established the importance of protocolised resuscitation including vasopressor use for MAP ≥ 65 mmHg, shaping sepsis management for the subsequent decade.</div>
      </div>
      <div class="tl-item">
        <div class="tl-year">2004</div>
        <div class="tl-event">First Surviving Sepsis Campaign guidelines published</div>
        <div class="tl-desc">SSC 2004 recommended dopamine or noradrenaline as first-line vasopressors with no preference, reflecting the evidence available at the time.</div>
      </div>
      <div class="tl-item">
        <div class="tl-year">2008</div>
        <div class="tl-event">VASST trial published — vasopressin vs norepinephrine in septic shock</div>
        <div class="tl-desc">Russell et al. (N Engl J Med) showed no mortality benefit of adding vasopressin vs adding norepinephrine. A subgroup with less severe shock showed a trend favouring vasopressin. This established vasopressin's role as a catecholamine-sparing adjunct rather than a primary agent.</div>
      </div>
      <div class="tl-item">
        <div class="tl-year">2010</div>
        <div class="tl-event">SOAP II trial — turning point for vasopressor selection</div>
        <div class="tl-desc">De Backer et al. (N Engl J Med) demonstrated that dopamine carried significantly higher arrhythmia rates (24.1% vs 12.4%, p &lt; 0.001) and was associated with higher mortality in cardiogenic shock. This profoundly changed prescribing practice in favour of noradrenaline.</div>
      </div>
      <div class="tl-item">
        <div class="tl-year">2012–2016</div>
        <div class="tl-event">Noradrenaline established as first-line vasopressor</div>
        <div class="tl-desc">SSC 2012 and 2016 guidelines formalised noradrenaline preference. The 2016 guidelines explicitly stated noradrenaline as the first-choice vasopressor (strong recommendation, moderate evidence), and discouraged dopamine except in selected patients.</div>
      </div>
      <div class="tl-item">
        <div class="tl-year">2016</div>
        <div class="tl-event">VANISH trial published</div>
        <div class="tl-desc">Gordon et al. (JAMA) compared vasopressin vs norepinephrine as the initial vasopressor, finding no difference in kidney failure-free days, though the vasopressin group needed less renal replacement therapy.</div>
      </div>
      <div class="tl-item">
        <div class="tl-year">2016</div>
        <div class="tl-event">Sepsis-3 definitions</div>
        <div class="tl-desc">Singer et al. (JAMA) published the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3), redefining septic shock as sepsis with vasopressor requirement to maintain MAP ≥ 65 mmHg and serum lactate &gt; 2 mmol/L despite adequate fluid resuscitation.</div>
      </div>
      <div class="tl-item">
        <div class="tl-year">2021</div>
        <div class="tl-event">SSC 2021 guidelines — consolidation and early initiation</div>
        <div class="tl-desc">Evans et al. maintained noradrenaline as first-line, added vasopressin (0.03 U/min) as the preferred second agent, emphasised early vasopressor initiation, and recommended against delaying vasopressors to complete fluid loading.</div>
      </div>
      <div class="tl-item">
        <div class="tl-year">2024–2025</div>
        <div class="tl-event">Emerging evidence for ultra-early initiation</div>
        <div class="tl-desc">Multiple meta-analyses (Shi et al. 2025, Ahn et al. 2024) suggest earlier initiation of noradrenaline (&lt; 1 hour of shock diagnosis) may reduce mortality and total fluid administration. Ongoing RCTs (VASOSHOCK and others) continue to investigate optimal timing strategies.</div>
      </div>
    </div>
  </section>

  <!-- ═══════════════════════════════ TAB: REFERENCES ═══════════════════════════════ -->
  <section id="refs" class="tab-content">
    <p class="section-heading">Literature</p>
    <h2 class="block-title">References</h2>

    <ol class="ref-list">
      <li>De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL; SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. <em>N Engl J Med.</em> 2010;362(9):779–789. DOI: 10.1056/NEJMoa0907118</li>

      <li>Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D; VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. <em>N Engl J Med.</em> 2008;358(9):877–887. DOI: 10.1056/NEJMoa067373</li>

      <li>Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, Mcintyre L, Ostermann M, Prescott HC, Schorr C, Simpson S, Wiersinga WJ, Alshamsi F, Angus DC, Arabi Y, Azevedo L, Beale R, Beilman G, Belley-Cote E, Burry L, Cecconi M, Centofanti J, Coz Yataco A, De Waele J, Dellinger RP, Doi K, Du B, Estenssoro E, Ferrer R, Gomersall C, Hodgson C, Møller MH, Iwashyna T, Jacob S, Kleinpell R, Klompas M, Koh Y, Kumar A, Kwizera A, Lobo S, Masur H, McGloughlin S, Mehta S, Mehta Y, Mer M, Nunnally M, Oczkowski S, Osborn T, Papathanassoglou E, Perner A, Puskarich M, Roberts J, Schweickert W, Seckel M, Sevransky J, Sprung CL, Welte T, Zimmerman J, Levy M. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. <em>Intensive Care Med.</em> 2021;47(11):1181–1247. DOI: 10.1007/s00134-021-06506-y</li>

      <li>Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, Pogson DG, Aya HD, Anjum A, Frazier GJ, Santhakumaran S, Prevost AT, Brett SJ; VANISH Investigators. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. <em>JAMA.</em> 2016;316(5):509–518. DOI: 10.1001/jama.2016.10485</li>

      <li>Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Miller RR, Moreno R, Morley J, Timsit JF, Trzeciak S, Dellinger RP. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. <em>Intensive Care Med.</em> 2017;43(3):304–377. DOI: 10.1007/s00134-017-4683-6</li>

      <li>Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). <em>JAMA.</em> 2016;315(8):801–810. DOI: 10.1001/jama.2016.0287</li>

      <li>Shi R, Braïk R, Monnet X, Teboul JL, Hamzaoui O. Early norepinephrine for patients with septic shock: an updated systematic review and meta-analysis with trial sequential analysis. <em>Crit Care.</em> 2025;29(1):182. DOI: 10.1186/s13054-025-05170-8</li>

      <li>Ahn C, Yu G, Shin TG, Cho Y, Park S, Suh GY. Comparison of early and late norepinephrine administration in patients with septic shock: a systematic review and meta-analysis. <em>Chest.</em> 2025;167(1):171–183. DOI: 10.1016/j.chest.2024.08.012</li>

      <li>Li Y, Zhang D, Li H, Wang Y, Zhang D. Effect of timing of norepinephrine administration on prognosis of patients with septic shock: a prospective cohort study. <em>J Intensive Med.</em> 2025;5(2):160–166. DOI: 10.1016/j.jointm.2024.09.003</li>

      <li>Vincent JL, De Backer D, Wiedermann CJ, Fukushima S, Yamakawa K, Antonelli M, Landoni G. Exploration of different statistical approaches in the comparison of dopamine and norepinephrine in the treatment of shock: SOAP II. <em>Crit Care.</em> 2024;28(1):371. DOI: 10.1186/s13054-024-05016-9</li>

      <li>Avni T, Lador A, Lev S, Leibovici L, Paul M, Grossman A. Vasopressors for the treatment of septic shock: systematic review and meta-analysis. <em>PLoS One.</em> 2015;10(8):e0129305. DOI: 10.1371/journal.pone.0129305</li>

      <li>Ospina-Tascón GA, Hernandez G, Alvarez I, Calderón-Tapia LE, Manzano-Nunez R, Sánchez-Ortiz AI, Quiñones E, Madriñán HJ, Valencia JD, Aldecoa C, De Backer D, García AF. Effects of very early start of norepinephrine in patients with septic shock: a propensity score-based analysis. <em>Crit Care.</em> 2020;24(1):52. DOI: 10.1186/s13054-020-2756-6</li>

      <li>Morales S, Wendel-Garcia PD, Ibarra-Estrada M, García-Salcido R, Aguirre-Avalos G, Escobar-Ortiz L, Teboul JL. The impact of norepinephrine dose reporting heterogeneity on mortality prediction in septic shock patients. <em>Crit Care.</em> 2024;28(1):216. DOI: 10.1186/s13054-024-05006-x</li>

      <li>Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. <em>N Engl J Med.</em> 2001;345(19):1368–1377. DOI: 10.1056/NEJMoa010307</li>

      <li>Dünser MW, Hasibeder WR. Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress. <em>J Intensive Care Med.</em> 2009;24(5):293–316. DOI: 10.1177/0885066609340743</li>

      <li>Hamzaoui O, Georger JF, Monnet X, Ksouri H, Maizel J, Richard C, Teboul JL. Early administration of norepinephrine increases cardiac preload and cardiac output in septic patients with life-threatening hypotension. <em>Crit Care.</em> 2010;14(4):R142. DOI: 10.1186/cc9207</li>
    </ol>
  </section>

  <!-- FOOTER -->
  <footer>
    <div class="footer-left">
      CCM Notes · FOAMed · Critical Care Clinical Reference<br>
      Updated January 2025 · Aligned with SSC 2021 · <a href="about.html" style="color:var(--accent); text-decoration:none; border-bottom:1px solid var(--border);">About</a><br>
      <span style="color:#c00; font-size:.68rem;">For educational use only. Always verify against local formulary and institutional protocols.</span>
    </div>
    <div class="footer-badge">Evidence-Based Medicine</div>
  </footer>

</div><!-- /shell -->

<script>
function showTab(id, btn) {
  document.querySelectorAll('.tab-content').forEach(t => t.classList.remove('active'));
  document.querySelectorAll('.nav-btn').forEach(b => b.classList.remove('active'));
  document.getElementById(id).classList.add('active');
  if (btn) btn.classList.add('active');
}
</script>

</body>
</html>
